Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma

References

• Son HS, Shin YM, Park KK, et al. Correlation between HER2 overexpression and clinicopathological characteristics in gastric cancer patients who have undergone curative resection. J Gastric Cancer. 2014 Sep;14(3):1–6.
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Ieni A, Barresi V, Rigoli L, et al. HER2 status in premalignant, early, and advanced neoplastic lesions of the stomach. Dis Markers. 2015;2015:234851. doi: 10.1155/2015/234851.
   Web of Science ®Google Scholar
• Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009 May 20;27(15S):4556.
   Google Scholar
• Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.
   PubMedGoogle Scholar
• Wang HB, Liao XF, Zhang J. Clinicopathological factors associated with HER2-positive gastric cancer: a meta-analysis. Medicine. 2017 Nov 1;96(44):e8437.
   Web of Science ®Google Scholar
• Amrani HJ, Marchoudi N, Sadaoui I, et al. Ki-67 expression in gastric cancer and correlation with clinico-pathological characteristics. Int J Sci Res Publ. 2014;4(6):254–258.
   Google Scholar
• Shien T, Kinoshita T, Seki K, et al. p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer. Acta Med Okayama. 2013;67(3):165–170.
   Web of Science ®Google Scholar
• Busuttil RA, Zapparoli GV, Haupt S, et al. Role of p53 in the progression of gastric cancer. Oncotarget. 2014 Dec;5(23):12016.
   Google Scholar
• Cancer incidence report Saudi Arabia, Kingdom of Saudi Arabia, Council of health services. Saudi cancer registry; April 2014 [cited 2015 Jun 4]. Available from: www.scr.org.sa
   Google Scholar
• Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012 Sep;3(3):251–261.
   PubMedGoogle Scholar
• Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer. J Clin Oncol. 2009;27:15s.
   Google Scholar
• Saricanbaz I, Karahacioglu E, Ekinci O, et al. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer. Asian Pac J Cancer Prev. 2014;15(19):8215–8219.
   Google Scholar
• Kataoka Y, Okabe H, Yoshizawa A, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013 Jan 1;16(1):84–93.
   Web of Science ®Google Scholar
• Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2‐positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2013 Apr 1;26(3):299–304.
   Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005 Feb 1;16(2):273–278.
   PubMed Web of Science ®Google Scholar
• Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014 Jan 1;17(1):34–42.
   Web of Science ®Google Scholar
• Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012 Sep 12;18:5992–6000. clincanres-1318.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Riches JC, Ku GY, et al. Conference: Gastrointestinal Cancers Symposium. Journal of Clinical Oncology. 2015;33(3): Supplement Meeting Abstract: 63.
   Google Scholar
• Choi WH, Lee S, Cho S. Microsatellite alterations and protein expression of 5 major tumor suppressor genes in gastric adenocarcinomas. Transl Oncol. 2018 Feb 28;11(1):43–55.
   Web of Science ®Google Scholar
• Babacan NA, Eğilmez HR, Yücel B, et al. The prognostic value of UHRF-1 and p53 in gastric cancer. Saudi J Gastroenterol. 2016 Jan;22(1):25.
   Web of Science ®Google Scholar
• Yıldırım M, Kaya V, Demirpence O, et al. Prognostic significance of p53 in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2015;16(1):327–332.
   Google Scholar
• Duffy MJ, Synnott NC, McGowan PM, et al. p53 as a target for the treatment of cancer. Cancer Treat Rev. 2014 Dec 31;40(10):1153–1160.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang L, Zhang JP, et al. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. World J Gastroenterol. 2010 Jan 21;16(3):339.
   Web of Science ®Google Scholar
• Lazăr DA, Tăban SO, Sporea I, et al. Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol. 2010;51(4):655–661.
   PubMed Web of Science ®Google Scholar
• Luo G, Hu Y, Zhang Z, et al. Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis. Oncotarget. 2017 Jul 25;8(30):50273.
   PubMedGoogle Scholar
• Ieni A, Barresi V, Giuffrè G, et al. HER2 status in advanced gastric carcinoma: a retrospective multicentric analysis from Sicily. Oncol Lett. 2013 Dec 1;6(6):1591–1594.
   PubMed Web of Science ®Google Scholar
• El-Gendi S, Talaat I, Abdel-Hadi M. HER-2/Neu status in gastric carcinomas in a series of Egyptian patients and its relation to Ki-67 expression. Open J Pathol. 2015 Aug 17;5(4):101.
   Google Scholar
• Wang S, HüTtmann G, Zhang Z, et al. Light-controlled delivery of monoclonal antibodies for targeted photoinactivation of Ki-67. Mol Pharm. 2015 Aug 13;12(9):3272–3281.
   Google Scholar